AVAC 2021 Work Plan - AVAC Engage
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
AVAC 2021 Work Plan
1. Introduction
AVAC faces, but is also well-prepared for, a significant year ahead. Externally, AVAC confronts an increasingly promising, but also increasingly complex,
HIV prevention research and rollout landscape. From multiple trials in different modalities concluding in the years ahead, to a changing landscape for
prevention trial design, to the prospect of more prevention products competing for attention and funding, AVAC has never been more needed. AVAC has
also expanded its brief and networks to build advocate understanding of and influence over the COVID-19 research enterprise, and to influence planning
and policy-making related to implementation and access for COVID prevention and treatment. At the same time, we are focused on ensuring that
progress in the global AIDS response continues even as significant resources and attention shift to COVID.
Internally, we are responding to the impact of COVID on our own operations, managing the development of a comprehensive 5-year strategic plan,
taking an active role in addressing EDI issues both in the organization’s internal operations and in our alliances with partners, initiating a new Partnership
Network Initiative, welcoming new board leadership and increasing our focus on resource renewal and diversification. This workplan is the product of a
collaborative organization-wide analysis of the opportunities and challenges AVAC will confront in 2021. It reflects our perspective on priority activities
that will make AVAC more focused, more influential and more responsive to the challenges of global environment in the year ahead. With the 2021
landscape in mind, AVAC has refined the organizational goals that will drive and inform our work in the year ahead. They are:
1. Champion comprehensive HIV prevention and sexual and reproductive health and rights: Advance advocacy around global HIV prevention and
SRHR through a community and human-centered lens, with a focus on ally-ship to the most affected populations.
2. Accelerate human-centered R&D, product development and introduction agendas: Guide and pressure developers, funders and policymakers
to ensure inclusive and comprehensive plans for all relevant populations for products entering and coming out of the research pipeline. Identify,
raise up, and advocate for reasonable, actionable ways to increase uptake and continuation rates for prevention methods through a people-
centered lens.
3. Advocate for equitable funding and access for new prevention options as viable choices: Work with our partners to influence and pressure
donors, governments, researchers, developers and implementers to ensure that policy, funding, research and delivery efforts are directed to the
geographies and populations with the most need, with a focus on diverse global and national-level partnerships to accelerate access. Advocate
for acceleration and equity in the delivery of new methods.
4. Advance the global movement: Continue to foster and sustain equitable and transparent partnerships with a global cadre of evidence-based,
impact-driven advocates in the co-creation and advancement of advocacy agendas identified as key priorities by affected populations using
inclusive, power-sharing models.
5. Diversify and update AVAC: Diversify AVAC’s staff, senior management, Board, partnerships and funding sources. Increase transparency, equity
and inclusion in our internal and external operations.
As in past years, AVAC’s workplan presents (2) a work plan summary of each of our program areas and desired outcomes for the year ahead; (3) a
COVID-specific summary; (4) a list of 2021 field-wide milestones that inform and are informed by AVAC’s work; and (5) a list of current major grants. An
inventory of each program’s activities and plans for the year is then included (6) and hopefully makes clear how each team’s activities link to the
advancement of our organization-wide goals.
AVAC 2021 Work Plan 1 December 20202. Workplan Summary
Program Areas 2021 Outcomes/Indicators
Objective Area 1: Research Engagement: • Advocates play an active, independent and leadership role with research entities; are aware of research
Shape the R&D environment through status, issues of concern and investments at the country level and linked to their advocacy work. Civil
advocacy for investment, political support society perspectives are reflected in various research agendas.
and GPP • Advocates play an active, independent and leadership role in advancing the women's prevention agenda.
They are aware of the gaps, barriers and issues of concern for women and girls. Civil society perspectives
are reflected in the women's prevention agenda.
• Stakeholders recognize and systematically implement GPP as critical to successful clinical research; a
model for GPP institutionalization is recognized and adapted.
• Dissemination of R&D information serves the needs of target stakeholders, primarily to ensure their
contribution to smooth, ethical trial conduct, outcomes and next steps.
• Inform key external audiences about COVID-19 R&D, and encourage communities to take public-health
action, promote public awareness, and counter misinformation.
Objective Area 2: Global Px Movement: • Advocacy partners are well-informed and are connected to each other as individuals, organizations and
Identify, support and connect an informed coalitions in ways that leverage their collective strengths to advance HIV and COVID-19 prevention
network of advocacy partners implementation and research advocacy.
• Partners are successful in achieving their advocacy objectives.
• Partners are able to engage in key events; advocacy network is visible and supports collaborative activity.
• Networks of communications focal points, journalists, advocates and scientists prepared for,
communicating about and engaged in accurate information dissemination.
Objective Area 3: Implementation • AVAC and partners’ implementation advocacy secures, via coalition-based work, shifts in policies, service
Advocacy: Improve evidence-base and delivery approaches and funding commitments for global HIV, with a particular focus on primary
rights-based investments in a prevention.
comprehensive response • Implementation advocacy team at AVAC works alongside Africa-based coalition(s) to advance an
integration agenda for SRHR and HIV prevention that changes awareness among activists of key concepts,
triggering or reinforcing demands that drive shifts in policy and procurement, with specific attention to
“multi-layered” prevention and works with Product Introduction to accelerate introduction of the dual pill.
• Implementation advocacy preserves and expands the financial resources needed for a comprehensive
response.
• AVAC’s network and influence help optimize the reach, effectiveness, and/or sustainability of critical
response activities to COVID-19 in-line with core AVAC principles.
AVAC 2021 Work Plan 2 December 2020Objective Area 4: Product Intro & Access: • Insights on end user preferences and segments result in the development and application of practical tools
Identify/anticipate needs & gaps and and interventions.
provide targeted tools, support & platforms • Lessons learned and continued research on product introduction are well-documented, disseminated to
to expand access to px inform decision-making, with plans to introduce and scale up available and pipeline products and inform
COVID-19 response.
• Donors, advocates, developers and implementers are aligned around comprehensive product
development and delivery plans.
• AVAC expertise informs product development and intro for therapeutics, vaccines, or point-of-care
diagnostics for COVID-19.
Cross-cutting 5: Program Management & • Cross-program coordination mechanisms are defined, deployed, and advance high-priority AVAC-wide
Coordination strategic initiatives.
• Internal information-sharing processes are implemented consistently; intellectual property is preserved
and shared effectively.
• Staff improve project and time management skills; use of project management tools is consistent and
formalized across AVAC; similar expectations and practices for “how work gets done” across the
workstreams.
• Relationship management practices and norms are set and followed across AVAC.
• Risk management practices and norms are followed across AVAC.
Cross-cutting 6: Policy, Data & Analytics • Policy advocacy and data analytics contribute to awareness and support for expanded and improved HIV
prevention research funding and prevention programming.
• Both HIV and COVID research funding, product development pipelines, and partnership/coalition efforts
are tracked and provided publicly as tools to ensure awareness and support, as well as to protect critical
HIV prevention funding.
• AVAC’s own programs and strategies are informed, developed and improved through robust MEL
processes.
Cross-cutting 7: Communications • AVAC’s external communications functions and approach adhere to best practices for an advocacy
organization of this size and scope.
Cross-cutting 8: Administration • AVAC fosters a culture of leadership, accountability, collaboration, and continuous improvement.
• Human Resources policies, processes, and practices are up-to-date, consistent, and support AVAC’s
organizational health.
• All systems are secure, easily accessible, user-friendly, and reliable.
Cross-cutting 9: Finance • Finance policies and procedures follow current best practices.
• Staff adhere to policies and procedures; there are no fines, disallowed expenses, and audit findings are
clean.
• Sub-grants operations are streamlined and support our programs
AVAC 2021 Work Plan 3 December 20203. AVAC 2021 Work Plan – COVID-19 Addendum
As the Covid-19 response evolves, including a likely shift from research to roll-out, there continues to be a strong rationale for AVAC to use its resources,
partnerships, and expertise to influence the global effort to combat the COVID-19 pandemic. While the next 12 months are difficult to forecast, we
anticipate that much of the conversation around Covid-19, and vaccines specifically, will revolve around:
Within this context, AVAC’s unique role to synthesize complex information to develop and implement smart, actionable biomedical prevention advocacy
and product introduction agendas to have meaningful and measurable impact remains both relevant, and urgently needed. AVAC will leverage its
existing expertise and networks to engage in the COVID-19 effort in areas where AVAC’s skills are clearly relevant and will add value. AVAC’s COVID-
specific goals are to:
• INFORM key audiences, including advocates, the media, and policymakers with a focus on ensuring our partners are informed on
intersections between COVID and HIV, including the impact of COVID on HIV research, to strengthen our advocacy
• ENGAGE with key audiences, including policymakers, funders, and developers to ensure ethical research conduct in COVID
• ADVOCATE for a COVID response that utilizes the lessons, skills, and infrastructure from HIV; protects critical gains in HIV so they are not
lost; and shapes the global health infrastructure of the future
AVAC 2021 Work Plan 4 December 2020Org. Objectives/Goals/Covid Sub-goals COVID-19 Actions
INFORM key audiences, including advocates, the media, and policymakers on intersections between COVID and HIV, including the impact of COVID on HIV
research, to strengthen our advocacy
Research Literacy: Synthesize and communicate complex information Develop and promote Covid-related resources on AVAC website
to enhance understanding of COVID-19 research and reinforce the Develop and sign-on to position statements, commentaries and opinion pieces in-
importance of science- and data-driven decision-making. line with AVAC principles
Engage in enhanced Social Media campaign around Covid response
Develop and participate in timely Covid-related webinars and virtual convening
ENGAGE with key audiences, including CSOs, policymakers, funders, and developers to ensure ethical and informed conduct of COVID research
Stakeholders recognize and systematically implement GPP as critical to Develop and deploy relevant GPP Essentials to ensure integration of participatory
successful clinical research; a model for GPP institutionalization is practice in Covid R&D
recognized and adapted for use with COVID-19. Engage in GPP advocacy and outreach to enhance GPP uptake w/in Covid R&D effort
Co-create and convene the Covid Advocates Advisory Board to Continue to ensure engagement of the CAAB in prioritized Covid research discussions
support the global COVID-19 research agenda Co-create and implement a role for the CAAB related to Covid-19 vaccine access
Ongoing participation in CAAB leadership group
Advocacy partners are well-informed and connected to advance HIV Provide real-time communications support to AVAC partners
and COVID-19 prevention implementation and research advocacy in- Other?
line with country-specific priorities.
ADVOCATE to demand equity and access to prevention and treatment tools for both COVID and HIV AND ensure that hard-won gains in the HIV/AIDS field
are not lost
Develop and promote Access-related resources on AVAC website
Engage with emerging multi-stakeholder partnerships and product developers to
Identify, apply, and help scale the usage of innovative products, approaches,
Help drive the discussion around equitable global access to Covid-19 technologies, financing, and platforms for access to vaccines (and other
vaccines interventions?);
Support the development of risk communication strategies that target and reflect the
realities of the most vulnerable populations (using rapid human-centered design
approach)
Protect HIV programs while facilitating synergies that support COVID research &
Protecting Global Gains: Continue to drive and grow an advocacy
programs
campaign articulating a post-COVID future of GH in line with AVAC
Expand AVAC’s network of influence
core principles
Apply COVID policies in research & programs to HIV
AVAC 2021 Work Plan 5 December 20204. Field-wide 2021 Context – a selective list of events, milestones, research highlights, etc., that influence (and/or influenced by) AVAC programs 2021 Highlights J F M A M J J A S O N D HIV R4P Virtual Conference x x MEL Journal articles (SPARC & COMPASS) x x COVID-19 Supplement for PEPFAR and GFATM x x PEPFAR COP21 Review Process x x x x Global Fund Strategy Development x x x x CROI x US President’s FY 22 Budget for NIH, PEPFAR and GFATM Released ? ? ? ? IAS 2021 x International Conf on Family Planning x INTEREST x ICASA 2021 x AMP results x Possible First Approvasl of Dapivirine Ring x x x Possible FDA Approval of CAB-LA x Bioequivalence results DPP x x x Launch of Islatravir efficacy trials x x Launch of Lenacapavir and F/TAF efficacy trials x x USAID RFPs on Microbicides, TBD ? ? ? ? ? ? ? ? ? ? ? AVAC 2021 Work Plan 6 December 2020
5. Major Current Grants Table
Funds/
Obligation
Current Project Funder Timeframe Amount Financial Implications Received as
of
12/31/2020 2021 2022 2023 2024 2025 2026
PMM: Prevention Market BMGF 02/16 - 03/21 $23,891,812 ● Annual grant payment recognized as revenue in $ 23,891,812
Manager for HIV year of receipt of payment Discussions underway for renewal from April 2021
Prevention
CASPR: Coalition to USAID 06/16 - 06/26 $39,991,778 ● Grant agreement has ten-year total with a $ 17,547,669 3,884,178 4,570,704 4,558,834 4,743,718 4,686,674
Accelerate & Support ceiling amount which is not guaranteed
Prevention Research
● Annual obligations made by USAID and added
to a Line of Credit from which we draw down
upon any expense and get reimbursed within 24
hours
● Revenue recorded only when reimbursed funds
are received
COMPASS Africa: Coalition BMGF 11/17 - 10/21 $ 6,215,028 ● Annual grant payment recognized as revenue in $ 8,524,294
to build Momentum, $ 2,309,266 year of receipt of payment Discussions for renewal from 11/21 pending Learning Assesment
Activism, Solidarity &
Strategy Africa
General operating BMGF 06/18 - 06/22 $13,200,000 ● Full revenue recorded in 2018 $ 9,900,000 3,300,000
support to advance ● Paid annually in June each year
HIV prevention
Development of launch plan CIFF 08/19 - 1/21 $ 1,235,455 ● Tranche 1: Initial 800k received Sept. 2019 $ 1,235,455 Discussions already underway for renewal from July 2021
for the Dual Protection Pill $ 500,000 ● Tranche 2: Balance due in July 2020
● Additional bridge funding of $500k Dec 2020
PROMISE: Preparing for FHI/USAID 6/20 - 5/21 $ 225,000 ● Grant agreement has one-year total with a $ 131,250 93,750
Ring Opportunities through ceiling amount which is not guaranteed
Market Introduction Support ● Annual obligations made by FHI 360 only when Awaiting USAID RFP for future microbicide funding
and Knowledge Exchange they receive obligation from USAID
● Revenue recorded only when monthly advance
payments are made
NEW 10/20 - 10/21 $ 250,000 ● Full payment expected prior to end of 2020 $ 250,000 Future funding pending initial planning grant
Strengthen/formalize role of
VENTURE
the Global AIDS Policy
FUND
Partnership (GAPP)
Highlighted section show changes since last report
AVAC 2021 Work Plan 7 December 20206. 2021 Consolidated Work Plan
Activity Outputs Indicators of success AVAC Goal
Objective Area 1: Research Engagement: Shape the R&D environment through advocacy for investment, political support and GPP
Goal 1.1: Enhance both demand and support for HIV biomedical prevention R&D from civil society, communities, policy makers and other key
stakeholders; support increased financial support for prevention R&D, including through identification of scientific gaps and effective info/data
sharing
1.1.1 Monitor the full HIV prevention research pipeline to Clear articulation of priorities and A diverse set of advocates Goal 2:
identify advocacy interests and opportunities for civil initial strategies that are rooted in play an active, independent Accelerate
society input on the design and conduct of upcoming trials, equity and prioritize access to and leadership role with human-
and to prepare for upcoming results products for all populations research entities. They are centered R&D,
1.1.1.a Monitor the implications of COVID-19 on the HIV aware of research status, product
research pipeline; map potential COVID-related issues of concern and development
delays/changes; identify engagement strategies to investments at the country and
communicate timeline shifts to stakeholders level and link them to their introduction
advocacy work. Civil society agendas
1.1.2 Conduct and/or support research engagement Effective consultations that increase perspectives are reflected in
consultations and follow-up. Due to COVID, this may be advocate awareness of and various research agendas
through a virtual consultation framework that can be engagement in key trials; meeting
shared/adapted by networks, research sites and internal reports highlighting stakeholder input
staff. Focus areas may include: on key issues and needed actions;
● Gilead F/TAF trial literacy and advocacy tools developed
● CAB-LA results dissemination and regulatory processes to meet identified needs
● AMP results, bNAb/combo trials
● Women’s agenda - MPTs/dap ring approval and post-
efficacy study/CAB-LA
● Dual pill (support Prod Intro)
● MTN 034/042/043
● Merck Islatravir monthly pill
● Ad26 rx program
● PrEPVacc
● Gilead Lenacapavir (GS-6207), Capsid inhibitor
● Merck Islatravir Implant
AVAC 2021 Work Plan 8 December 2020Activity Outputs Indicators of success AVAC Goal
1.1.3 Develop and implement research engagement Engagement leads to an increased
mechanisms for specific trials (e.g., F/TAF, combo bNAbs, prioritization of advocacy
Merck monthly pill), broader research agendas (e.g., PrEP interests/concerns by the field;
for women) or broader issues (e.g., next-gen trial design) Scoping and defining mechanism(s)
may include: call notes/meeting
reports; trial design materials for
advocates
1.1.4 Continue work of the Trial Design Academy to stay Advocates’ perspectives and
abreast of latest concepts and developments, and to consolidated priorities for next-gen
engage with trialists and regulators; consolidate trials are incorporated into trial
tools/materials for advocates on Engage; in response to designs and regulatory decision-
COVID, facilitate virtual engagements, revise cure fellow making
work plans and extend timelines for fellowship; seek
additional funding for these program/timeline changes as
appropriate
1.1.5 Facilitate broad civil society engagement in cure Meeting report articulating
research through continuation and expansion of IAS-AVAC commitments from attendees and
Cure Academy, possible expanded engagement with cure concrete ways AVAC and IAS can
research collaboratories support research translation
1.1.6 Develop and disseminate HVAD research literacy Updated HVAD literacy content;
content; conduct web and social media outreach with report-backs from community
partners; support community/ advocacy activities on or activities
around HVAD; link messaging to COVID-19 as appropriate,
highlighting the lessons learned between HIV and COVID
vaccine development, and to the broader agenda of
expanding vaccine confidence
1.1.7 Facilitate advocates’ engagement with regulatory Regulatory implications mapped
processes for trials and product approval (e.g., lessons according to R&D pipeline; advocates’
learned from DVR, tracking CAB-LA submission, trial design priorities are articulated and influence
trainings for regulators (focus on Africa), global regulatory regulatory decisions/processes
coordination
AVAC 2021 Work Plan 9 December 2020Activity Outputs Indicators of success AVAC Goal
1.1.8 Implement work plan for new strategic partnerships Scope of work and/or Terms of A diverse set of advocates Goal 1:
focused on the development of women’s health options in Reference for subgrant(s); final work play an active, independent Champion
Africa; address implications of COVID-19 on women’s health plans and leadership role in comprehensive
and well-being, MPT development and HIV/SRH integration advancing the women's HIV prevention
Strategy for SRH strengthening is prevention agenda. They are and sexual and
developed, and coordinated across aware of the gaps, barriers reproductive
CASPR and AVAC more broadly and issues of concern, such health and
as gender equity and rights
1.1.9 With CASPR and other partners, build advocacy for a Ongoing stakeholder engagement inclusion, for women and
robust rx agenda for women’s multipurpose prevention, around SRH integration (with HC-HIV girls. Civil society
and to support research for women in all their diversity; Advocacy WG, cisgender women’s perspectives are reflected in
ensure agenda includes gender considerations for COVID-19 group); linked to Engage SRH group the women's research
agenda
HIV px rx pipeline includes
considerations for pregnant and
breastfeeding women, dap ring
approval, lessons from dual pill
Materials include key advocacy
messages/statements; literacy
materials; campaigns
1.1.10 Conduct a women’s SRH summit, led by African Advocacy statement; advocacy actions
women advocates for HIV prevention and SRH advocates,
focused on addressing gaps in women-centered prevention
within the R&D pipeline [*in collaboration with Prod Intro];
make alternate plans for virtual engagement as needed
1.1.11 Support in-country consultations (Kenya and Consultation reports
Zimbabwe) to explore the need, market potential,
opportunities and anticipated challenges of introducing a
combined oral contraceptive/ PrEP dual pill [*led by Prod
Intro; Rx Eng to support]
Goal 1.2: Enhance GPP globally as a means to efficient, ethical trial conduct and community/civil society readiness for new HIV prevention biomedical
tools
AVAC 2021 Work Plan 10 December 2020Activity Outputs Indicators of success AVAC Goal
1.2.1 Continue GPP training through global online course GPP training evaluations Stakeholders recognize and Goal 2:
offerings, adapted online/blended training programs, systematically implement Accelerate
research/institution/trial-specific trainings; and support to GPP as critical to successful human-
in-person trainings; implement a TOT program to provide clinical research; a model for centered R&D,
support for additional trainers GPP institutionalization is product
recognized development
1.2.2 With TB Alliance, Janssen and possibly others, develop Pilot and dissemination of short course and
a condensed online GPP training for use at sponsor level; introduction
consider using as a compliance tool with other GXP agendas
trainings
1.2.3 Continue promotion of Engage as a platform for User satisfaction surveys; metrics
capacity building and participatory engagement in core demonstrate utilization of the
groups (SRH, clinical trial design, CoP and RLNZ) and platform; new content driven by user
courses; frame Engage as a strategic platform during feedback/participation
COVID-19 to help build interest.
1.2.4 Consolidate GPP experiences across diseases to Initial drafts for peer-reviewed
elevate stakeholder engagement community of practice publications, case studies and/or tools
1.2.5 Support partners to develop tools that expand GPP GPP leadership training curriculum;
implementation; strategically disseminate C19 Trials Theory of Change; SETER Course;
Considerations doc to research groups and advocates, gender framework analysis; C19 Trials
support implementation as needed Considerations
Goal 1.3: Develop and maintain strategic research literacy platforms to synthesize, explain and disseminate emerging issues and trial results for a
broad array of stakeholders
1.3.1 Develop a series of basic animations that illustrate At least three videos that can be Dissemination of basic R&D Goal 2:
and build literacy around foundational concepts in HIV posted on Engage and shared with information that reflects Accelerate
prevention and COVID-19 research and trial designs trial design academy participants equity, diversity, inclusion, human-
and de-colonized language, centered R&D,
1.3.2 With partners, lead research literacy efforts directed Articles/blogs/podcast; conference and that serves the needs of product
at advocates, journalists and lay audiences around relevant activity, media cafe report-backs target stakeholders, development
conferences and forums (e.g., HIVR4P CROI, HIV 2021, primarily to ensure their and
ICASA) and focused on key developments and debates in
AVAC 2021 Work Plan 11 December 2020Activity Outputs Indicators of success AVAC Goal
the field; identify ways to build literacy and facilitate contribution to smooth, introduction
engagement at virtual conferences Engage ethical trial conduct, agendas
outcomes and next steps
1.3.3 Develop additional learning content and tools as Tools, concepts, pilots
necessary for activities and programs on Engage, in line
with user feedback
Objective Area 2: Global Prevention Movement: Identify, support and connect an informed network of advocacy partners
Goal 2.1 Through the Fellows Program, support emerging advocates to inform, influence and transform HIV prevention in their communities
2.1.1. Support 2020 Fellows - through extended Fellowship Fellows’ project workplans clearly Moving the dial in key Goal 4:
grants - to update and implement strategic projects linked articulate objectives and activities processes in tangible ways Advance the
to community/country priorities and aligned with AVAC focused on achievable, strategic wins related to the Fellows’ global
objectives. 2020-2021 Project goals include: that help advance priority prevention project goals, including well- movement
goals for their communities and in line articulated demands; shifts
● Strengthening platforms for SRHR and HIV prevention with broader CSO coalitions. in funding; policy changes;
● Working in coalition, in particular with young women, advocacy
LGBTI communities, sex workers and with other AVAC Fellows lead, present and participate messages/demands
programs and country coalitions in key meetings, events and articulated by others; place
● Preparing for HIV prevention research milestones discussions that advance their agendas at decision-making spaces
including CAB-LA regulatory processes, AMP study and priorities of their networks. that did not exist before or
results, the start of the Islatravir study and F/TAF trial were limited.
for women and tracking REACH, Deliver, B-Protected Final accomplishments will include key
and ongoing HIV and COVID vaccine and bNAb trials wins as well as enhanced capacities,
● Increasing access to HIV prevention tools with a focus skills and understanding and linkages
on dapivirine ring introduction, dual ring product of the
development, regulatory processes for CAB-LA, coalitions/organizations/networks
expanded and differentiated access to oral PrEP and they have engaged.
treatment in a comprehensive platform
● Leading U=U and Test & Treat campaigns Additional outputs include blogs, fact-
● Supporting resource mobilization, with a focus on sheets, policy briefs, media articles
PEPFAR 2021, GFATM and increasing domestic and other tools that either document
resources these efforts, help move the
● Integrating advocacy to demand equity and access to discussion forward and/or help others
future prevention and treatment tools for both COVID
AVAC 2021 Work Plan 12 December 2020Activity Outputs Indicators of success AVAC Goal
and HIV, specific to community priorities and CS to support knowledge building in HIV
campaigns prevention advocacy.
Goal 2.2: Launch Fellows 2.0 using inclusive, power-sharing models to ensure it continues to be an important foundational advocacy program for HIV
prevention
2.2.1 Define Fellows 2.0 program scope and future plans Develop alumni, host and stakeholder Innovative Fellows 2.0 Goal 4:
based on Impact Evaluation findings and recommendations working groups program builds on strengths Advance the
and includes power-sharing global
models for peer mentoring, movement
support and training.
2.2.3 Commemorate 10th anniversary of Fellows program Outputs and products that Celebration/acknowledgme
communicate the impact of Fellows nt of the lessons from the
program on HIV prevention advocacy, Fellows Program is shared at
to include video and social media selected events with
campaigns; infographics; and mapping broader stakeholders.
Fellows’ impact on the field
Goal 2.3: Through PxROAR, support peer-to-peer communities of practice for key advocates around community HIV prevention priorities
2.3.1 EROAR: Support Mosaico community engagement GPP/community engagement sessions Local communities of sites Goal 4:
with EATG and HVTN, through virtual GPP/community with Mosaico vaccine sites in Poland, reached; strong, allied Advance the
engagement sessions with vaccine sites. Spain and Italy are attended by CABs support and buy-in of global
and local MSM/Trans communities, vaccine research and movement
with the goal of vaccine research preparedness achieved;
acceptability and ownership positive, accurate media
coverage secured
2.3.2 EROAR: Influence country-specific milestones for oral EROAR members are updated, Advocacy projects
PrEP access; spotlight regulatory processes for CAB-LA; and engaged and help influence specific completed with tangible
engage /link EROAR partners in COVID research platforms HIV prevention priority targets outcomes/ wins such as
through virtual quarterly RAVES, webinars with key demand creation and
researchers and small advocacy grants disbursement regulatory and funding
preparedness
2.3.3 EROAR: In partnership with PrEPster, launch (GPP-HPI) Broad dissemination and uptake of GPP SOP for implementation
Guidelines for HIV Prevention Implementation, to guidelines/SOP for community recognized as important
AVAC 2021 Work Plan 13 December 2020Activity Outputs Indicators of success AVAC Goal
standardize community engagement in the rollout of new engagement in rollout of HIV resource and begins to be
and existing prevention, as a complement to GPP for prevention programs and campaigns adopted by programs
research
2.3.4 AROAR: Utilize small grants to strengthen knowledge Advocacy projects that are context- Projects produce well-
building, community engagement and advocacy actions on specific and conducted in articulated demands and
regulatory processes on the CAB-LA dapivirine ring collaboration with relevant networks tangible outcomes/wins
with strategic asks such as demand creation,
regulatory and funding
preparedness for eventual
access
2.3.5 TGRoar: Onboard new TG ROAR team from Research New TG ROAR team of up to 5 New cadre of TG ROARers
Agenda project members formed continue their work to
integrate acceptance of
Agenda in research settings
and within trans networks
2.3.6 Support research literacy updates with AROAR, Research literacy team produces Literacy updates feed into
TGROAR members in collaboration with Rx engagement effective updates on HIV prevention advocacy plans for LAI, ring,
team pipeline dual pill and engagement
around HIV and COVID
vaccines
2.3.7 Work with ImpAd on the development of an AVAC- Consultation with select KPs Consultations feed into and
wide KP strategy that consults with AROAR, TGROAR implemented inform overall KP strategy
members and other AVAC partners engaged on KP for AVAC
prevention advocacy work
2.3.8 US ROAR: Develop US ROAR 2.0, a new strategy for Zoom RAVE strategy session for 2021 Internal and external
engagement planning, with follow-up actions as agreement on US priorities
determined through consultation and how to get there
2.3. 9 Continuing from 2020 the collaboration with TG Launch trans-Agenda at R4P or Commitments from research
community partners, launch and promote a TGNB-driven another appropriate venue; execute a entities and trans networks
research agenda that achieves the support of trans promotional strategy for its adoption to achieve the Agenda
networks and research entities priorities
AVAC 2021 Work Plan 14 December 2020Activity Outputs Indicators of success AVAC Goal
with the Technical Advisory Group and
new TG ROARers
2.3.10: Develop a research literacy training and trial design A cadre of advocates are prepared to Trained and fluent ROARers
engagement, linked with AVAC research literacy team, for influence outcomes of AMP, Mosaico, feed into advocacy plans for
all ROAR teams dual pill, COVID vax, etc. LAI, ring, dual pill
preparation and community
engagement around HIV and
COVID vaccines
Goal 2.4: Help ensure accurate and supportive media coverage of HIV prevention research and implementation in key African countries, in partnership
with media partners
2.4.1 With Internews and media cafe partners, continue to Trainings, webinars, materials, and Journalists demonstrate an Goal 4:
strengthen the media cafe program to enhance the connections to key experts in the field expanded knowledge of Advance the
knowledge and skills of key journalists reporting on HIV R&D, development and global
prevention and COVID. 2021 focal points include: 6 cross-cafe collaborations in trainings introduction agendas, are movement
• Implementing the program in partnership with the up-to-date on key
conveners; 4 renewed grants country media café developments in the field
• Strengthening access to updated information, including programs and are better equipped to
AVAC-generated data; and links to AVAC's network of report on complex and
advocates, researchers, policy-makers, implementors, Launch of Malawi café program nuanced topics in HIV
representatives of key populations and other experts Cohesive journalist training program at prevention
• Maintaining creative platforms for peer-to-peer sharing, major conferences.
including a conveners' gathering
• Ensuring a gender lens is applied across training and
cafes.
2.4.2 Develop and implement cohesive regional journalist Trainings successfully implemented Media coverage is more
trainings linked to milestones/issues in R&D around key R&D issues (e.g., ring roll comprehensive, accurate
out, AMP, LAI and COVID and/or linked and nuanced; AVAC reaches
to major conferences e.g., IAS, ICASA, new journalists and builds
Interest, CROI); journalists linked to greater interest in and
AVAC network capacity for HIV R&D
reporting
AVAC 2021 Work Plan 15 December 2020Activity Outputs Indicators of success AVAC Goal
2.4.3 Build out South Africa media-engagement network SA journos have an improved Media coverage of HIV px
through work with Internews on community media understanding of HIV px landscape in research, implementation
program and outreach to top tier SA journos; explore SA; community media is linked more and access in South Africa is
possible partners in SA; consult with relevant research and effectively to ongoing research more accurate and nuanced
implementation partners on needs through Comms WG projects
2.4.4 Work with Internews to pilot the "Telling the HIV story Media cafe conveners are comfortable Cafes and journos share
curriculum" journalist training; finalize curriculum and with and using the curriculum to train more stories; quality of
conduct training of trainers program. others; curriculum is updated to stories improves
reflect current situation
2.4.5 Support conveners to develop and implement a new New awards program developed; Cafes and journos share
program to award cafes and individual journalists for best awards on HIV px and COVID given at more stories; quality of
stories on HIV and COVID19 coverage. end of year stories improves
2.4.6 Support conveners in documenting cafes, including Reports, calls, shared info across Quality of program is
successes and challenges; work with conveners to share AVAC; more cafe SPARC stories improved as lessons learned
experiences across the program and refine AVAC systems and best practices are
for documenting and sharing media cafe activities and implemented
other media engagement activities; Incorporate MERL (see
COMPASS for ex.) into cafe program; output: blogs, joint
publication (journal), abstracts
2.4.7 Continue to support HIV prevention communications Information and messages shared; Information shared across
working group to share information, messages and periodic calls the field
strategies
Goal 2.5: Expand the pool of informed HIV prevention advocates. Strengthen advocacy capacity of existing and new HIV prevention advocates
2.5.1 Finalize the Engage ‘Advocacy Navigator’ mentoring Online mentoring platform up and Strong interest and Goal 4:
program to support civil society and other stakeholders to running; alumni Fellows mentors are applications to participate in Advance the
develop strategic advocacy plans linked to transferring skills to new advocates the program; strong interest global
national/community platforms; train alumni Fellows as from alumni Fellows in movement
online mentors for Phase 1 launch; develop innovative participating as mentors;
MERL plan and plans for expansion. active co-management of
content curation by alumni
Fellows
AVAC 2021 Work Plan 16 December 2020Activity Outputs Indicators of success AVAC Goal
2.5.2 Provide ongoing support to existing and emerging CS engagement on emerging issues Network of partners makes
advocate groups and networks interested in HIV prevention clear progress toward
research advocacy Strategies aligned with partners and achieving their advocacy
programs (including AFHNI, national objectives. Partners are
px advocacy groups) well-informed about trends
and issues in HIV R&D and
leverage each other's
strengths to advance their
advocacy
2.5.3 Coordinate advocates’ activities at R4P, including the Multiple opportunities created to Advocates feel engaged and
Advocates Pre-conference and Advocates’ Corner, to highlight advocacy contribution to HIV empowered to share their
support advocates’ visible engagement in the conference; px research and implementation and knowledge and experiences;
promote the Falobi Award as a way to recognize the ensure advocates’ perspectives are new and continuing
contributions of advocates to HIV Prevention Research highlighted at the conference and in advocacy alliances are
Advocacy media coverage of HIVR4P formed; conference
discussions, debates and
media coverage consistently
include advocacy
perspectives
Goal 2.6: Advocacy partners are able to link to global efforts to engage, inform and advocate for accelerated introduction of the dapivirine vaginal ring
through integrated HIV/SRHR platforms
2.6.1 With CASPR, COMPASS, PMM and advocacy partners, Advocacy plans are context specific, Plans produce country- and Goal 1:
provide financial and technical support to AVAC CS partners linked to national priorities and region-tailored strategies, Champion
to develop and implement strategic advocacy plans to include advocacy to accelerate and/or including core demands, comprehensive
accelerate the introduction of the dapivirine ring. influence national regulatory targets and tactics with HIV prevention
processes, ring guidelines, policy and tangible wins. and sexual and
demand creation plans. Plans link reproductive
advocates to PROMISE partners, IPM health and
and other relevant implementing rights
partners and include a small grants
program, learning symposiums, peer-
network platform and close
AVAC 2021 Work Plan 17 December 2020Activity Outputs Indicators of success AVAC Goal
engagement with other advocacy
initiatives.
2.6.2 Foster an enabling media environment for the Messaging documents shared and Coordinated and region-
dapivirine ring through message alignment in the updated based on user feedback; specific messaging is
communications working group, media cafe program and positioning op eds shared and incorporated into media
regional trainings published coverage of the ring,
influencing public
perceptions, regulatory
action and ring interest and
uptake
Objective Area 3: Implementation Advocacy: Improve evidence-base and rights-based investments in a comprehensive response
Goal 3.1: Concrete, actionable primary-prevention and HIV-SRHR-integration “asks,” advocacy and evidence-gathering incorporated into
transnational coalition work, particularly in East and Southern Africa
3.1.1 Continue to inform the primary prevention agenda Community-led monitoring tools that Key decision makers and Goal 3:
advanced by CSOs in the global north and working at document PrEP, HIV-SRHR, VMMC and fellow advocates act in Advocate for
country-level advocacy differentiated service delivery for ART response to clearly equitable
in Malawi, Tanzania, Uganda and articulated activist demands funding and
Zimbabwe; findings reports that and positions access for new
remediate problems; replication of prevention
best practices options as
viable choices
3.1.2 Facilitate research to roll out “handoff” for px Development of a “language-justice”- Use of “language-justice” Goal 1:
products with new approvals and/or pending approvals derived message/advocacy agenda derived message/advocacy Champion
that encompasses PEPFAR and GFATM agenda in public-facing comprehensive
language on Dap Ring, cis-women’s documents and forums, HIV prevention
perspective on CAB-LA, oral PrEP including PEPFAR COP and sexual and
investments guidance and docs reproductive
developed by GAPP and in health and
demands to national rights
country-level policy makers
AVAC 2021 Work Plan 18 December 2020Activity Outputs Indicators of success AVAC Goal
3.1.3 Build activist impact on GFATM programming Development and documentation of Coalition-work yields more Goal 3:
tools, support approaches, tactics that GFATM data transparency Advocate for
help “hack” the GFATM to gain shifts and tools that help coalition equitable
in programming, visibility into partner partners put the data to use funding and
performance and more access for new
prevention
options as
viable choices
3.1.4 Support advocacy to maintain essential health COVID-specific impact assessment Impact mitigation actions Goal 3:
services and mitigate the health, social and economic tools (developed, compiled in 2020) taken based on tools Advocate for
impact of intersecting pandemics in the three COMPASS are used/updated in 2021 looking at assessments; uptake and equitable
focus countries KP, SRHR-HIV, DSD issues; domestic use of the resource funding and
resource mobilization advocacy pivot mobilization messaging at access for new
to looking at synergy/risk/positioning country and global level prevention
of HIV within COVID, pandemic options as
preparedness and UHC agendas – viable choices
including “transition memo” for
potential new US president; AVAC
Report 2021 content; tailored tools –
webinar, landscape analysis etc. for
coalition partners
3.1.5 Participate, via exchange of technical support and Increased adoption of policy and Context-specific campaigns Goal 4:
skills, in country-based coalition efforts in Malawi, Tanzania, program approaches that strengthen and sets of “asks” (e.g., Advance the
Uganda, Zimbabwe and other priority countries to shift combination prevention, through PEPFAR COP and global
barriers to comprehensive HIV responses differentiated service delivery and Global Fund) advanced to movement
other components of a sustainable, shift barriers
comprehensive and integrated HIV
response Strengthened advocacy by
key partners leads to
Increased analysis and advocacy increased identification of
capacity among key influencers in well-framed (evidence-
support of HIV and health sector based) budget and financing
financing related barriers (as
identified in country
AVAC 2021 Work Plan 19 December 2020Activity Outputs Indicators of success AVAC Goal
landscapes) addressed over
reporting cycle
Goal 3.2: AVAC is a trusted member of a robust, rights-based implementation advocacy coalition that centers PLHIV, people at risk of HIV and civil
society leaders in the African countries where ImpAd work is centered
3.2.1 Shift “center of gravity” for ImpAd grant-making - Development of structured Pending COMPASS Goal 4:
management and MERL to African partners trainings/support to 1-2 COMPASS extension/funds availability Advance the
partners as part of “on-ramp” to for 2022 – MANET/CEDEP global
making and managing subgrants and/or PZAT begin making movement
subgrants within ImpAd
workplan
3.2.2 Support civil society globally, regionally and Coalition in Zambia advances agenda Zambia KPIF coalition Goal 4:
specifically in Kenya, Tanzania, Nigeria and Zambia to for engagement and program agenda adopted; activists Advance the
engage with Key Population Investment Fund in ways that structure for KPIF implementation understand PEPFAR global
result in programs that engage KP-led groups – including as indicators and approaches movement
direct funding recipients – and result in positive shifts in Data for advocacy training to data presentation and
service delivery and health outcomes implemented for Zambia KP funding mechanisms and
Consortium members using peer begin engagement with
training model – KP-led groups in proven strategies for
Zambia are equipped with skills and winning shifts in
knowledge to analyze data and build implementation
effective data-driven advocacy arrangements for KPIF-fund
campaigns programs, leveraging
additional investments from
Through peer-led and AVAC facilitated the government and GFATM
peer training and mentorship, KP-led and securing commitments
groups in Kenya, Nigeria, Tanzania and from stakeholders to
Zambia have organizational capacity to implement approaches
receive and manage KPIF funds based on best practices
directly
Increased investment in KP
Cohort of KP expert peer mentors programming in Zambia in
engaged to support their CSO peers to COP 2021
AVAC 2021 Work Plan 20 December 2020Activity Outputs Indicators of success AVAC Goal
strengthen organizational capacity and KP-led CSOs in Kenya,
data-informed advocacy. Nigeria, Tanzania and
Zambia receive KPIF funds
directly
3.2.3 Coordinate and support efforts of global and local KPIF is rolled out with advanced Global CSOs and In-country Goal 4:
CSOs to engage with KPIF Implementing partners, USAID engagement/collaboration of KP CSOs CSOs adopt engagement and Advance the
and CDC. in-country, including proposal design, monitoring plan including global
safety and security plan as well as a coordinated bi-monthly movement
plan for community-led M/E of KPIF webinar with IPs and
USAID/CDC
3.2.4 Provide technical and financial support to country- Strengthened coalitions advocating for Year-Four COMPASS Goal 4:
based teams in Malawi, Tanzania and Zimbabwe and data-informed policy and program coalition “landscape Advance the
Northern allies to analyze/document, map landscape approaches to strengthen a analyses” and strategic global
including actors’ positions, identify barriers, and execute comprehensive HIV response in action plans (beginning year movement
and evaluate campaigns to shift barriers in favor of a Malawi, Tanzania and Zimbabwe 4) and CCATS and SPARC
comprehensive response stories (mid-2021 and end
2021) reflect clarity on the
structure of a strong
campaign, data use and a
grasp of tactics
3.2.5 Provide in-country MERL support to country coalitions 1-2 webinars about COMPASS MERL COMPASS partners take up Goal 4:
to reinforce training and practical application of MERL tools, approaches, learnings and potential on-demand MERL support Advance the
reinforce the importance of MERL for advocacy campaigns for adaptation from PZAT and AVAC and global
and respond to specific requests from partners show improvement in areas movement
Improved documentation of COMPASS identified for support based
campaigns, wins, challenges, lessons on baseline and post-
learned, etc. using C-CAAT and SPARC support assessment
tools
1-2 Africa-based COMPASS
Program management/MERL capacity partners demonstrate
building training for 1-2 partners as capacity to make and
AVAC 2021 Work Plan 21 December 2020Activity Outputs Indicators of success AVAC Goal
on-ramp to Africa based grantmaking manage COMPASS sub-
and grant management with robust grants
MERL component
3.2.6 Document successes, challenges, and lessons learned Website design and launch Web site designed and Goal 4:
from North-South coalition-based advocacy work launched Advance the
Case studies global
3 case studies on COMPASS movement
Monthly reports partner advocacy campaigns
written
Monthly all-COMPASS calls
12 monthly COMPASS
MERL reports reports developed
12 monthly COMPASS calls
conducted and documented
3.2.7 Submit funding renewal request for COMPASS 2.0 Continued multi-year funding renewal New grant awarded in 2021
request for North-South advocacy from BMGF for continued
coalition for a comprehensive HIV COMPASS work
response with AVAC as prime
3.2.8 Develop grant manual for COMPASS sub-grantees Grant manual Manual developed
Improved quality of grant deliverables Manual rolled out to
and quicker turnaround time with COMPASS sub-grantees
reporting and payments
3.2.9 Transfer all COMPASS sub-grant related files into the More intuitive, easy-to-use file COMPASS sub-grant files
new filing system on AVAC share drive management system moved into new system
AVAC 2021 Work Plan 22 December 2020Activity Outputs Indicators of success AVAC Goal
3.2.10 Train sub-grantees on AVAC financial and grants Webinars, zoom trainings 4 quarterly webinars
management (e.g., how to complete a finance report) conducted for groups that
through webinars/zoom calls Improved quality of grant deliverables need extra grants
from sub-grantees management support
3.2.11 Train AVAC COMPASS team on new sub-grants Sub-grants management software All AVAC COMPASS
management software training developed and implemented; program/grant managers
AVAC COMPASS grant management trained in and using new
team trained and comfortable using software
new sub-grants management software
Objective Area 4: Product Intro & Access: Identify/anticipate needs & gaps and provide targeted tools, support & platforms to expand access to px
Goal 4.1: Leverage and expand product intro platform to develop comprehensive product intro strategies for multiple products (i.e., ring, CAB-LA, dual
pill, monthly pill)
4.1.1 Lead and adapt BioPIC and PMM to coordinate, track Implement and refine BioPIC product- Donors, advocates, Goal 2:
and monitor investments and introduction of multiple adaptable framework to improve developers and Accelerate
products (CAB-LA, ring, dual pill, monthly pill etc.) in the planning for next-gen products implementers are aligned human-
context of expanding HIV px portfolio around comprehensive centered R&D,
Adapt governance structure to reflect product development and product
both product-specific and cross- delivery plans; one development
cutting delivery considerations additional developer and
formalizes collaboration introduction
Engage community advisory boards with PMM/BioPIC; new agendas
and groups to inform product biomedical prevention
adoption decisions, strengthen products are rolled out in a
implementation, foster demand way that supports and
creation complements the needs of
communities
4.1.2 Provide technical and strategic support to IPM, USAID Strategic plan of action to guide and Funds mobilized to support
and PROMISE Consortium for ring introduction and access coordinate introduction efforts ring introduction in at
planning finalized and implemented minimum 5 countries
AVAC 2021 Work Plan 23 December 2020Activity Outputs Indicators of success AVAC Goal
4.1.3 Lead and coordinate market introduction planning for Secretariat to Advisory board Product introduction
the DPP; refine and articulate a comprehensive market planned in a coordinated
introduction strategy for DPP Organize regulatory forum to identify and strategic manner with
national regulatory pathway and eased entry to regulatory
requirements approval
Disseminate market introduction Donor commitments
strategy to key donors and secured to support further
stakeholders development and
introduction of the pill and
Finalize and disseminate investment to move into the second
case for dual pill to various donors phase of the project
4.1.4 Guide design of and ensure coordination across demo Key questions identified and Greater coordination across
projects for the ring, DPP and CAB-LA socialized; sub-study implementing demo projects; better
partners understand different alignment of projects with
segments and patterns of use across stakeholder priorities
different delivery channels
4.1.5 Strengthen delivery platforms to include integrated, Promising and proven strategies for Health systems better
differentiated and sustainable models to increase access, integrated HIV px and SRH and prepared to deliver a wide
drive uptake and support continued use of the ring, DPP, simplifying PrEP delivery are array of HIV Px products
CAB-LA documented and implemented
Continue to support HIV/SRH
integration policies and service
delivery in Kenya and Zimbabwe
Launch new initiatives (i.e., innovation
challenge) with local partner to design
and implement innovative strategies
to strengthen delivery platforms and
“do PrEP differently”
4.1.6 COVID-19 Frontline of Access: Developments related to COVID access Civil society input on
Help drive the discussion around curated and synthesized to support decision-making related to
AVAC 2021 Work Plan 24 December 2020Activity Outputs Indicators of success AVAC Goal
equitable global access to COVID vaccines, therapeutics and partner advocacy; resources COVID vaccine access and
diagnostics developed and disseminated; webinar distribution is strengthened
series held to inform advocates
Specific actions and opportunities for
advocacy identified in collaboration
with partners
Goal 4.2 Amplify proven demand side solutions to inform, influence and improve product development and HIV prevention programs
4.2.1 Disseminate learnings from pilots in South Africa to Dissemination meetings held in South At least 2 implementers Goal 2:
inform cost-effective, feasible, scalable and sustainable Africa and globally /partners incorporate Accelerate
approaches for more women-centered HIV prevention learnings into ongoing human-
programming programs centered R&D,
product
development
and
introduction
agendas
4.2.2 Build on “user” insights and lessons learned from oral Analysis of demand generation to Demand generation
PrEP and contraception to develop tailored demand support introduction of ring, CAB-LA strategies in place and
generation strategy for the ring, CAB-LA and DPP at national and DPP developed; messages and funded for more effective
and community levels tools tested and refined with women; product introduction
costed models for effective demand
generation created
4.2.3 Collaborate with developers to act on and incorporate Updated end-user insights across New products designed and
product preferences, attributes and insights in early populations (especially MSM, FSW in packaged based on
product development planning Africa) and contexts mapped as prevailing preferences of
resource for donors, implementers people most likely to use
and developers; findings from human- them
centered design and research shared
with clinical researchers, NIH and
product developers
AVAC 2021 Work Plan 25 December 2020You can also read
